Analysis of pharmaceuticals and drug related impurities using Agilent instrumentation

Meaning of Topic

Impurity profiling in pharmaceuticals ensures drug safety, efficacy, and compliance with regulatory standards. Advanced liquid chromatography workflows are critical for detecting trace impurities—from organic by-products and degradation products to residual solvents and inorganic elements—across the drug value chain. High-performance and ultra-high-performance LC systems paired with complementary detectors and robust method development tools streamline impurity identification, quantification, and routine quality control.

Objectives and Overview of Studies

This selection of Application Notes demonstrates how to:

• Optimize and transfer HPLC methods from conventional to ultra-high-pressure LC platforms
• Qualify and validate Agilent 1290 Infinity and 1200 Series systems per USP <1058> guidelines
• Develop rapid, high-resolution separations for small-molecule analytes such as anesthetics, vitamins, beta-blockers, and analgesics
• Evaluate the analytical performance of the compact Agilent 1120 LC for routine impurity testing

Methodology and Used Instrumentation

All studies employed Agilent LC platforms with tailored configurations:

• Agilent 1290 Infinity LC: Binary Pump with integrated vacuum degasser, low-volume Jet Weaver mixing, Thermostatted Column Compartment, high-speed autosampler, and DAD detector
• Agilent 1200 Series LC: Quaternary or Binary Pump, standard autosampler, Column Compartment, and DAD or MS detectors
• Agilent 1120 Compact LC: Gradient Pump, compact column oven, easy-to-use autosampler, and variable-wavelength UV detector

Column chemistries ranged from ZORBAX StableBond and Eclipse Plus C18/C8 packing in 1–5 µm particle sizes to Waters BEH and RRHD phases for sub-2 µm separations. Gradient and isocratic protocols were optimized for analyte classes using ammonium buffers, ion-pair reagents, or TFA modifiers in water–acetonitrile or water–methanol systems.

Main Results and Discussion

• Transfer of conventional 3.5 µm LC methods to 1.7 µm columns on 1290 Infinity LC reduced analysis times by up to 80 % while maintaining resolution (Rs > 2.0) and sensitivity (linear R² > 0.999).
• Frictional heating at high flow rates on sub-2 µm columns was mitigated by minor column temperature adjustments, preserving critical selectivity.
• Instrument qualification per USP <1058> on the 1290 Infinity LC demonstrated precision (area RSD < 2 %; retention time RSD < 0.5 %) and linearity (R² > 0.999) for metoclopramide impurity profiling.
• The compact 1120 LC successfully replicated rapid resolution LC methods for water-soluble vitamins and Metoprolol degradation products, showing equivalent precision and resolution with simpler operation.
• OD-PABA impurity screening on the 1290 Infinity LC revealed sub-0.1 % degradant peaks within minutes, with UV/dAD detection across multiple wavelengths.
• Paracetamol and related impurities (A, B, F, H, I, J, K) were analyzed on both 1120 Compact and 1200 Series LCs, meeting pharmacopoeial system suitability criteria and providing comparable chromatographic performance.

Benefits and Practical Application

These workflows enable pharmaceutical labs to:

• Accelerate impurity method development and transfer to routine QC platforms
• Reduce solvent consumption and analysis time by up to fivefold
• Ensure regulatory compliance through built-in qualification tools and robust system design
• Use a single vendor portfolio for LC, detectors, and software to simplify training and maintenance

Future Trends and Possibilities

• Wider adoption of UHPLC columns in routine QC, supported by low-dispersion LC systems and high-pressure capability
• Increased use of high-resolution mass spectrometry (TOF, Q-TOF) for comprehensive impurity elucidation alongside LC separations
• Integration of automation and predictive method translation tools to further shorten method transfer times
• Expansion of chemometric approaches for accelerated condition scouting and data processing in impurity profiling

Conclusion

Agilent’s LC portfolio—from the compact 1120 to the high-end 1290 Infinity LC—provides flexible, high-performance solutions for impurity analysis in pharmaceuticals. By coupling optimized column chemistries, precision instrumentation, and dedicated software utilities (Method Translator, MassHunter), laboratories can achieve rapid, high-resolution impurity profiling that meets stringent regulatory standards and enhances overall laboratory productivity.

References

• USP Chapter <1058> Analytical Instrument Qualification
• Agilent Application Note 5990-4994EN, “Stepwise upgrade to high speed separation of anesthetics on the Agilent 1290 Infinity LC system”
• Agilent Application Note 5990-4781EN, “Analytical instrument qualification and system validation according to USP <1058> for the Agilent 1290 Infinity LC system”
• Agilent Application Note 5990-4379EN, “Determination of water soluble vitamins with the Agilent 1120 Compact LC after method development with the Agilent 1200 Series Rapid Resolution LC system and back transfer”
• Agilent Application Note 5990-4322EN, “Determination of degradation products of Metoprolol tablets with the Agilent 1120 Compact LC after method development with the Agilent 1200 Series RRLC system”
• Agilent Application Note 5990-4293EN, “Screening impurities in fine chemicals using the Agilent 1290 Infinity LC system”
• Agilent Application Note 5990-3981EN, “Increasing productivity in the analysis of impurities in metoclopramide hydrochloride formulations using the Agilent 1290 Infinity LC system”
• Agilent Application Note 5990-XXXXEN, “Development, validation, and comparison of an HPLC method to analyze paracetamol and related impurities according to the European Pharmacopoeia and USP using the Agilent 1120 Compact LC and the Agilent 1200 Series LC system”